dopa

Racemetirosine is an inhibitor of Tyrosine 3-monooxygenase, and consequently it inhibits the synthesis of catecholamines.

6-Hydroxy-L-DOPA is the 6-hydroxy derivative of the amino acid L-DOPA with neurotoxic properties. Exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to the highly potent and catecholamine-selective neurotoxin, 6-Hydroxydopamine.

D-α-Methyl DOPA is an inhibitor of DQ8 peptide binding to MHC class II molecules. By occupying a binding site in the DQ8 peptide groove, D-α-Methyl DOPA prevents the DQ8 peptide from associating with MHCII molecules. This action blocks presentation to CD4+ T cells, thereby slowing or hindering the onset or progression of type 1 diabetes or celiac disease.

dopamine receptor activator

[18F]-Labeled L-dopa precursor is used in the synthesis of 18F-labeled L-dopa[1].

Fmoc-Lys-Gly-Dopa-OH is a tripeptide that forms aggregates in aqueous solution through phase separation. These aggregates, with the assistance of Fe3+, offer a viable material for engineering the surfaces of mammalian cells.

L-Dopa precursor-1 (Compound 5a) is the precursor of 18F-L-Dopa. Serving as the core basis for a radiolabeling precursor, L-Dopa precursor-1 facilitates the introduction of non-metal radioactive elements through radiolabeling reactions. This compound can be utilized in studies related to renal denervation (RDN) surgery for refractory hypertension and chronic kidney disease.

L-DOPA methyl ester (LDME) is an agonist of dopamine D1 receptor.

Methyldopa (MK-351), an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.

L-DOPA belongs to the category of dopamine precursors, serving as an orally active neurotransmitter metabolic precursor capable of crossing the blood-brain barrier and undergoing conversion to dopamine within the brain. The compound exhibits anti-hyperalgesic properties and finds application in Parkinson's disease research as well as in the induction of disease models.

DL-Dopa is a phenylalanine beta-hydroxylated derivative.

Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.

Etilevodopa is an ethyl-ester prodrug of Levodopa which is used for the treatment of Parkinson's disease (PD). It is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Levodopa is the direct precursor of dop

Etilevodopa hydrochloride (L-DOPA ethyl ester) is a prodrug of levodopa. It also has greater gastric solubility and significant brain penetration.

6-Hydroxy-DOPA is an allosteric inhibitor of RAD52, it inhibits proliferation of BRCA-deficient cancer cells in vitro and also inhibits APE1.

DPBX-L-Dopa is a boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors.

3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)

3-O-Methyldopa (3-OMD) is the primary metabolite of L-DOPA formed by COMT. It serves as a clinical biomarker in Parkinson's disease research to monitor L-DOPA metabolism and pharmacological response.

L-DOPA-D6 is the deuterium-labeled analog of L-DOPA. L-DOPA (T0848) (Levodopa) serves as an orally active metabolic precursor to the neurotransmitter dopamine. It is capable of crossing the blood-brain barrier and is subsequently converted into dopamine within the brain. L-DOPA (T0848) exhibits anti-hyperalgesic properties and holds potential for Parkinson's disease research.

L-DOPA-13C is the 13C labeled version of L-DOPA. L-DOPA (T0848) (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and is transformed into dopamine within the brain. L-DOPA (T0848) exhibits anti-nociceptive properties and holds potential for Parkinson's disease research.

L-DOPA-13C6 is L-DOPA (T0848) labeled with 13C. L-DOPA (Levodopa) serves as an orally active metabolic precursor to the neurotransmitter dopamine. It can cross the blood-brain barrier and is converted to dopamine in the brain. L-DOPA (T0848) exhibits anti-nociceptive effects and shows potential in Parkinson's disease research.

L-DOPA-2,5,6-D3 is a deuterated isotope of L-Dopa for isotope tracing. L-DOPA (T0848) is an orally active metabolic precursor of the neurotransmitter dopamine, capable of crossing the blood-brain barrier and converting to dopamine within the brain. It exhibits anti-hyperalgesic effects and is utilised in Parkinson's disease research.

L-DOPA (Standard) is a reference standard for research and analysis in studies involving L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and be converted into dopamine in the brain. L-DOPA exhibits anti-hyperalgesic effects and holds potential in Parkinson’s disease research, and it can also be used to induce Parkinson’s disease models.